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management in children with single and
dual diagnosis of type 1 diabetes mellitus
and coeliac disease
Mary Mackinder1, Gavin Allison2, Vaios Svolos1, Elaine Buchanan3, Alison Johnston2, Tracey Cardigan3, Nicola Laird3,
Hazel Duncan3, Karen Fraser3, Christine A Edwards1, Ian Craigie2, Paraic McGrogan1,3 and Konstantinos Gerasimidis1*Abstract
Background: The consequences of subclinical coeliac disease (CD) in Type 1 diabetes mellitus (T1DM) remain unclear.
We looked at growth, anthropometry and disease management in children with dual diagnosis (T1DM + CD) before
and after CD diagnosis.
Methods: Anthropometry, glycated haemoglobin (HbA1c) and IgA tissue transglutaminase (tTg) were collected prior
to, and following CD diagnosis in 23 children with T1DM+ CD. This group was matched for demographics, T1DM
duration, age at CD diagnosis and at T1DM onset with 23 CD and 44 T1DM controls.
Results: No differences in growth or anthropometry were found between children with T1DM+ CD and controls at
any time point. Children with T1DM+ CD, had higher BMI z-score two years prior to, than at CD diagnosis (p < 0.001).
BMI z-score change one year prior to CD diagnosis was lower in the T1DM+ CD than the T1DM group (p = 0.009).
At two years, height velocity and change in BMI z-scores were similar in all groups. No differences were observed in
HbA1c between the T1DM+ CD and T1DM groups before or after CD diagnosis. More children with T1DM+ CD had
raised tTg levels one year after CD diagnosis than CD controls (CDx to CDx + 1 yr; T1DM+ CD: 100% to 71%, p = 0.180
and CD: 100% to 45%, p < 0.001); by two years there was no difference.
Conclusions: No major nutrition or growth deficits were observed in children with T1DM+ CD. CD diagnosis does not
impact on T1DM glycaemic control. CD specific serology was comparable to children with single CD, but those with
dual diagnosis may need more time to adjust to gluten free diet.
Keywords: Coeliac, Diabetes, Glycaemic control, Growth, NutritionBackground
Coeliac Disease (CD) is an aberrant immunological re-
sponse to ingestion of dietary gluten in individuals with
genetic predisposition, causing villous atrophy, crypt
hyperplasia in the mucosa of the small intestine and nutri-
ent malabsorption. [1]. The typical clinical presentation of
‘classical’ CD includes poor linear growth and nutritional
status, abdominal pain and distension, diarrhoea and iron* Correspondence: Konstantinos.Gerasimidis@glasgow.ac.uk
1Human Nutrition, School of Medicine, College of Medicine, Veterinary and
Life Sciences, Royal Hospital for Sick Children, University of Glasgow, G3 8SJ
Glasgow, UK
Full list of author information is available at the end of the article
© 2014 Mackinder et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.deficiency anaemia [2]. Adherence to a lifelong gluten free
diet (GFD) is the sole mainstream management approach
for CD. Highly specific and sensitive serological auto-
immune markers such as IgA anti-endomysial (EMA) and
IgA tissue transglutaminase (tTg) are now used for routine
screening of CD; enabling the identification of ‘silent’ and
‘atypical’ forms which do not express the ‘classical’ features
of symptomatic CD [3].
Individuals with Type 1 diabetes mellitus (T1DM) are at
increased risk of developing CD [4]. Genetic predispos-
ition [5], young age at T1DM onset [6], female gender
[7] and early introduction of gluten in the infant’s diet
[8,9] have been associated with an increased risk oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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substantial occurrence of CD in people with T1DM (2-
12%), routine serological screening of those at increased
risk remains controversial [10].
A review of the recent primary literature demonstrated
that in those health services that practise routine serological
screening for CD in people with T1DM, anthropometry
and growth parameters were reported to be within the
normal reference values at the time of CD diagnosis
[7,11-14] (Additional file 1: Table S1). However children
with dual diagnosis did not grow as well as their T1DM
peers, [7,15] presenting with greater deficits in weight
[7,15,16], height [16,17] and BMI z-scores [15,16]. In con-
trast, in two studies in centres without regular screening,
growth and nutritional status deficits were more pro-
nounced in children with T1DM+CD [16,17] (Additional
file 1: Table S1).
It has been suggested that the destruction of the small
bowel mucosal architecture in those with T1DM but
undiagnosed CD, causes malabsorption of nutrients which
may cause reduction in glycated haemoglobin A1c (HbA1c)
levels [14,16,18], lower insulin requirements [11,12] and
increase the frequency of self-reported severe hypogly-
caemic episodes (Additional file 1: Table S1). Yet the
evidence remains inconsistent and other studies have
reported no difference in HbA1c levels [7,12,13,17], nor
in the number of severe hypoglycaemic episodes [7,13-17]
(Additional file 1: Table S1). Inconsistency of study results
(Additional file 1: Table S1) may be caused by differences
in cohort size, study design, absent or poorly matched
control groups [11,16], lack of data on compliance to GFD
[7,11,14,15,19], inaccurate self-reporting of glycaemic
episodes, varied screening practices, availability of diet-
etic support among health centres and the duration of
CD diagnosis delay (Additional file 1: Table S1). Thus
far, no study looked at the impact of dual diagnosis on
the management of CD and compliance with gluten
free diet (GFD).
In the current study we determined the pattern of
growth, anthropometry and disease management of CD
and T1DM prior to and after the diagnosis and treatment
of CD in screen detected and endoscopically diagnosed
children with T1DM+CD and compared these against
precisely matched control groups of children with single
diagnosis of T1DM or CD.
Methods
The present study included children with T1DM, CD or
dual diagnosis (T1DM + CD) regularly attending the
relevant outpatient clinics at the Royal Hospital for Sick
Children, Glasgow, UK. Data were extracted from two
prospective clinical databases held by the local depart-
ments of Paediatric Gastroenterology, Hepatology and
Nutrition and Paediatric Diabetes. At the time of thestudy, the T1DM database contained 1203 people with
T1DM treated locally from 2000 to 2012. Individuals
were reviewed routinely every 3–4 months. Information
on growth parameters (e.g. height) and nutritional sta-
tus (e.g. weight and BMI), and HbA1c, as an index of
glycaemic control, were recorded in the database at
each clinical assessment. From 2002, T1DM children
were screened at diagnosis and at 2 year intervals for
specific CD serological markers, anti-endomysial anti-
bodies (EMA) and from 2003 tTg, or IgG EMA in the
case of IgA deficiency. Those with positive serology
underwent endoscopic investigations to confirm diag-
nosis. Those diagnosed with CD based on the Marsh
criteria were advised to follow a GFD.
From this cohort, 45 children with T1DM were diag-
nosed with CD. For the purposes of this study we selected
all children with a T1DM history longer than 2 years prior
to CD diagnosis to eliminate the characteristic weight
faltering prior to T1DM diagnosis and weight gain associ-
ated with initiation of exogenous insulin. The selected
participants had no other chronic medical condition,
and had anthropometric data available for two years
prior and two years post CD diagnosis. In total, there
were 23 children with T1DM + CD who fulfilled these
criteria. These were matched (1:2 since there were at
least twice as many children) for age, sex, age at T1DM
onset and duration of T1DM to a group of children
(n = 44) with only T1DM. Similarly the T1DM+CD group
were matched (1:1) for age, sex, age at CD diagnosis to
a control group of CD (n = 23) obtained from the gastro-
enterology clinical database of 293 CD children under the
care of the local clinical team from 1997 to 2012. Children
with CD were seen in the coeliac outpatients clinic at 3,
6 and 12 months after initial diagnosis and annually
thereafter. Information on growth parameters (e.g. height),
and nutritional status (e.g. weight and BMI) and tTg as a
proxy of disease management and compliance with GFD,
were collected during each hospital visit.
Data handling
The children with T1DM+CD were considered the pri-
mary comparison group and anthropometric measure-
ments were taken at CD diagnosis and one year and two
years prior to and post diagnosis (Figure 1). Both the CD
and T1DM children were matched to the T1DM+CD
group at each time point (Figure 1). Height, weight and
BMI z-scores were calculated using the 1990 UK reference
data [20]. Growth velocity and changes in nutritional
status were computed as the difference (Δ) in height
z-scores and BMI z-scores between CD diagnosis and the
time points one and two years before and after diagnosis.
BMI was classified as ‘Thin’ (BMI ≤ −2SD), ‘Normal weight’
(−2SD < BMI < 2SD) and ‘Obese’ (BMI ≥ 2SD). Similarly
participant height was classified as ‘Short’ or “Normal” if
+1yr
Height, Weight, BMI and HbA1c
+2yr
Height, Weight, BMI and HbA1c
CD+T1DM
T1DM Control
-1yr
-1yr
-2yr +1yr +2yr
Height, Weight and BMI and tTg
Height, Weight, BMI HbA1c and tTg
CD Diagnosis
CD control
+1yr +2yrCD Diagnosis
CD Diagnosis
Height, Weight, BMI HbA1c and tTg
-2yr
Figure 1 Study design with data collected at each time point of the follow up.
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disease activity and compliance with gluten free diet, was
classified based on the tTG levels [‘Normal’ (tTg < 7 U/ml)
and ‘Abnormal’ (tTg ≥ 7 U/ml) [21]]. Likewise in children
with T1DM, metabolic control was classed into ‘Optimal’
(HbA1c <7.5%) and ‘Suboptimal’ (HbA1c ≥7.5%)] at each
time point. In addition for patients with diabetes the
median HbA1c (%) was calculated from the six clinical
assessments before and after CD diagnosis to serve as a
long term proxy index of metabolic control T1DM.
Statistical analysis
Chi-squared and Fisher’s exact test were used to assess
differences in qualitative data (e.g. frequency of abnormal
HbA1c between people with T1DM+CD and T1DM).
For continuous non-parametric data, differences be-
tween groups were tested with the Kruskal-Wallis and
Mann–Whitney U tests. Comparison of means of nor-
mally distributed data was carried out with 2-sample
t-test. One sample t-test was used to assess deviations
of height z-scores from the national reference data
(UK 1990) and paired t-tests and 1-sample Wilcoxon
tests to assess differences within a single group at
different time points. Pearson correlation was used
to assess the linear association between continuous
variables. P-value <0.05 were considered statisticallysignificant. Minitab (version 16, UK) was used for data
analysis.
Ethics
Caldicott Guardian Approval from the National Health
Service was granted to carry out this study.
Results
Subject characteristics
From a total of 1203 T1DM children who received care
at the local hospital 45 (3.7%) were also diagnosed
with CD. Those with dual diagnosis (T1DM + CD) were
younger at diabetes onset [mean ± SD, years: (5.4 ± 0.7
vs 7.4 ± 6.4; p = 0.011)] than the remaining cohort of
T1DM children (n = 1158). Likewise children with
T1DM + CD were diagnosed with CD at an older age
[mean ± SD, years: (10.8 ± 4.3 vs 7.3 ± 2.8, p < 0.001)]
than the entire cohort of children with CD (n = 293).
The 23 children with T1DM + CD who fulfilled the
inclusion criteria of the study were representative of all
the 45 T1DM+CD children (22 were excluded: 2 second-
ary concomitant illness, 4 recently diagnosed and 16
missing data), with no significant differences regarding sex
and age at diagnosis of CD or T1DM (p = 0.853, p = 0.239
and p = 0.790 respectively). As expected there were no
significant differences in sex [Males; T1DM + CD: 11/
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T1DM diagnosis (mean ± SD; T1DM + CD: 5.3 ± 3.4;
T1DM: 5.0 ± 3.1; years), age at CD diagnosis (mean ± SD;
T1DM+CD: 10.7 ± 2.8; CD: 10.7 ± 2.9; years) and duration
of T1DM at CD diagnosis (mean ± SD; T1DM+CD: 5.4 ±
3.2; T1DM: 5.6 ± 3.2; years), between the groups (Table 1).
Growth and nutritional status
Comparison against the UK 1990 reference data
In children with T1DM+CD, height, weight and BMI
z-scores were not significantly different to the UK reference
values at any time point of the study (Table 2). Children
with CD had significantly lower height z-scores at CD diag-
nosis (CDx), at one (CDx + 1 yr) and two (CDx + 2 yrs)
years post diagnosis compared to the UK 1990 reference
population data [Height z-score, mean ± SD: (CDx: −0.72 ±
0.97, p = 0.002; CD + 1 yr: −0.63 ± 1.19, p = 0.023 and
CDx + 2 yrs:-0.32 ± 0.76, p = 0.044)] (Table 2). In the
same group, BMI and weight z-scores did not deviate
from the national norms at any time point of the study
(Table 2). Children with T1DM had no differences in
BMI or height z-scores from the reference population,
however they were heavier for their age at the majority
of time points [weight z-score, mean ± SD: (CDx-1 yrs:
0.26 ± 0.83, p = 0.05; CDx: 0.36 ± 0.85, p = 0.008; CDx +
1 yrs: 0.30 + 0.85, p = 0.027; CDx + 2 yrs: 0.29 ± 0.81,
p = 0.032)] (Table 2).
Comparison between groups at different time points
Mean measurements of height, weight and BMI z-scores
were similar between the T1DM + CD and CD control
group at all the time points. Similarly, there were no
significant differences in height or BMI z-scores between
the T1DM+CD and T1DM controls before or after CD
diagnosis (Table 2). In the latter groups, children with
T1DM+CD tended to be lighter (weight z-score) than
those with T1DM two years prior to diagnosis, at CD
diagnosis and one year after CD diagnosis although
the mean difference did not reach statistical signifi-
cance [T1DM + CD vs T1DM: weight z-score, mean ±
SD: (CDx-2 yrs: −0.21 ± 1.30 vs 0.33 ± 0.85, p = 0.08,Table 1 Subject characteristics of children with coeliac diseas
diagnosis (T1DM+ CD)
Number of participants (n)
Gender (M/F: n/percentage)
Age at T1DM diagnosis (years; mean ± SD)
Age at CD diagnosis (years; mean ± SD)
Duration of T1DM on CD diagnosis (years; mean ± SD)
Coeliac Disease (CD), Type 1 Diabetes Mellitus (T1DM).CDx: −0.19 ± 1.26 vs 0.36 ± 0.85, p = 0.07 and CDx +
1 yr −0.19 ± 1.26 vs 0.36 ± 0.85, p = 0.06)] (Table 2).
Two years prior to CD diagnosis, the change in BMI
z-score (ΔBMI z-score) did not differ between T1DM
children and those with T1DM+CD. However at one year
prior to CD diagnosis, the ΔBMI z-score was negative and
significantly lower in the T1DM+CD than the T1DM
children whose mean ΔBMI z-score increased [ΔBMI
z-score, mean ± SD: T1DM + CD: −0.17 ± 0.4 vs T1DM:
0.14 ± 0.5, p = 0.009)]. One and two years post-diagnosis,
there were no significant differences in nutritional status
(ΔBMI z-score) and growth velocity (ΔHeight z-score)
between any of the three groups.
Changes within each group before and after CD diagnosis
In the children with T1DM+CD, BMI z-score was sig-
nificantly higher two years prior to CD diagnosis than
at CD diagnosis [BMI z-score, mean ± SD: (CDx-2 yrs:
0.14 ± 0.95 vs CDx: −0.03 ± 1.62, p < 0.001)]. This was not
observed in the T1DM controls (Table 2). Compared to
CD diagnosis, BMI z-score did not change at any of the
follow up time points (Table 2). There were no differences
in height or weight z-scores in any group before and after
CD diagnosis (Table 2).
Glycaemic control between T1DM and T1DM + CD
In both T1DM+CD and T1DM groups, HbA1c (%) sig-
nificantly increased after CD diagnosis (baseline) [HbA1c,
mean ± SD: (CDx to CDx + 2 yrs, T1DM+CD: 8.1 ± 1.1%
to 8.5 ± 1.1%, p < 0.05 and T1DM: 8.3 ± 1.1% to 8.6 ± 1.1%,
p < 0.05)] (Figure 2). Mean HbA1c (%) did not differ
between the T1DM + CD and T1DM and neither did
the proportion of children with raised HbA1c levels (≥7.5%
HbA1c) at any time point (Figure 2). Similarly there was no
significant difference between T1DM+CD and T1DM
groups regarding the median of all cumulative HbA1c
measurements collected preceding (n = 6) or following
(n = 6) CD diagnosis [Mean ± SD HbA1c %, T1DM +
CD vs T1DM: (CDx-2 yrs to CDx: 8.2 ± 0.8 vs 8.2 ± 0.8,
p = 0.917 and CDx to CDx + 2 yrs: 8.4 ± 0.9 vs 8.4 ± 1.0;
p = 0.923)]. In the T1DM+CD, there were no differencese (CD), type 1 diabetes mellitus (T1DM) and dual
T1DM+ CD T1DM CD
23 44 23
M: 11/48% M: 21/48% M: 11/48%
F: 12/52% F: 23/52% F: 12/52%
5.3 ± 3.4 5 ± 3.1 n/a
10.7 ± 2.8 n/a 10.7 ± 2.9
5.4 ± 3.2 5.6 ± 3.2 n/a
Table 2 Nutritional status and growth of children with coeliac disease (CD), type 1 diabetes mellitus (T1DM) and dual
diagnosis (T1DM+ CD)
Mean ± SD* Condition CDx-2 yrs CDx-1 yrs CDx CDx + 1 yr CDx + 2 yrs
BMI z-score, (SD) T1DM + CD 0.14 ± 0.952 0.14 ± 0.90 −0.03 ± 1.01 −0.04 ± 0.99 0.07 ± 1.02
CD n/a n/a 0.09 ± 1.09 0.13 ± 1.23 0.27 ± 1.18
T1DM 0.49 ± 1.02 0.26 ± 0.95 0.39 ± 0.92 0.37 ± 0.9 0.27 ± 0.92
BMI classification, Th/N/Ob (n) T1DM + CD 0/23/0 0/23/0 1/21/0 1/22/0 1/17/0
CD n/a n/a 1/21/1 0/21/1 1/13/3
T1DM 0/40/3 0/43/1 0/43/1 0/41/1 0/38/1
Height z-score, (SD) T1DM + CD −0.44 ± 1.38 −0.36 ± 1.26 −0.26 ± 1.21 −0.32 ± 1.10 −0.38 ± 1.61
CD n/a n/a −0.72 ± 0.971 −0.63 ± 1.191 −0.32 ± 0.761
T1DM −0.11 ± 0.78 0.03 ± 0.72 0.05 ± 0.77 −0.05 ± 0.72 0.07 ± 0.69
Height classification Short/Normal (n) T1DM + CD 2/21 2/20 2/21 2/21 3/15
CD n/a n/a 3/20 1/21 0/16
T1DM 0/43 0/44 0/44 0/44 0/39
Weight z-score, (SD) T1DM + CD −0.21 ± 1.30 −0.12 ± 1.26 −0.19 ± 1.26 −0.2 ± 1.04 −0.15 ± 1.48
CD n/a n/a −0.31 + 0.83 −0.22 ± 0.89 0.06 ± 1.02
T1DM 0.33 ± 0.85 0.26 ± 0.831 0.36 ± 0.851 0.30 + 0.851 0.29 ± 0.811
Coeliac Disease (CD), Type 1 Diabetes Mellitus (T1DM), CDx: Coeliac Disease diagnosis; CDx + 1: One year post Coeliac Disease diagnosis; CDx + 2: Two years post
Coeliac Disease diagnosis; CDx-1: One year prior Coeliac Disease diagnosis; CDx-2y: Two years prior Coeliac Disease diagnosis; HbA1c: Glycated haemoglobin A1c;
tTG: Tissue Transglutaminase; BMI: Body mass index; Th/N/Ob: number of thin/normal BMI/obese participants; 1p < 0.05 to UK 1990 reference data; 2p < 0.001
between CDx and each time points; *unless otherwise is specified; n/a: data for CD were not available prior to disease diagnosis.
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levels before and after CD diagnosis. No significant
correlations were observed between HbA1c levels and
tTg concentrations at CD diagnosis or one or two years
after CD diagnosis (Pearson correlation; CDx: r = −0.214,
p = 0.409, CDx + 1 yr: r = 0.370, p = 0.193, CDx + 2 yrs:
r = 0.167, p = 0.553).
Compliance to a GFD in CD and T1DM + CD groups
Mean tTg concentrations did not differ between the
children with T1DM + CD and CD at diagnosis and
during follow up (Figure 2). Compared to CD diagnosis,
plasma tTg concentrations significantly decreased one
and two years after treatment with GFD in both groups
(T1DM + CD and CD) (p < 0.001) (Figure 2) indicating
compliance to the GFD. However a significantly higher
proportion of children in the T1DM + CD group had
raised tTg levels (>7.0 U/ml) one year after CD diagno-
sis compared with the CD controls (CDx to CDx + 1 yr;
T1DM + CD: 100% to 71%, p = 0.18 and CD: 100% to
45%, p < 0.001) (Figure 2). At two years post diagnosis
the difference in the percentage of children with abnor-
mal tTg levels was no longer different (T1DM + CD:
40% vs CD: 38%, p = 0.943) and both groups had signifi-
cantly fewer children with raised levels compared with
CD diagnosis (p < 0.001) (Figure 2).Discussion
This study characterised the growth, nutritional status
and management of CD and T1DM in children with
dual diagnoses before and after the diagnosis of CD by
comparison with a matched cohort of CD and T1DM
controls. Such aspects make this study unique and over-
come the limitations of previous research [7,11,12,14,16]
(Additional file 1: Table S1). In summary, the findings of
this study suggest that the dual diagnoses of CD and
T1DM do not affect the nutritional status, growth and
disease management of either condition. This is in accord-
ance with previous studies which reported no difference
in the growth patterns of children with T1DM+CD at
CD diagnosis compared with their peers with T1DM
(14–16) but contrary to others, who found deterioration
of linear growth [7,17], weight [7,17,22,23] and BMI z-
scores [23] both at and post CD diagnosis (Additional
file 1: Table S1). Inconsistency between studies may be
explained by differences in screening practices between
health centres, delayed diagnosis of CD and variations
in sample size or sample selection bias by comparing
groups of participants with different characteristics
(Additional file 1: Table S1). Indeed, studies that reported
similar results to the current study were located in centres
which had annual screening programs for CD in people
with T1DM. In studies where CD screening was not
010
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Figure 2 Levels (line) and percentage (bars) of participants with raised HbA1c and tTG in children with Coeliac Disease (CD), Type 1
Diabetes Mellitus (T1DM) and dual diagnosis (T1DM+DM). Top panel: Left axis displays percentage (bars) of participants with raised HbA1c
(>7.5%); right axis displays mean (lines) HbA1c levels (%) with error (SEM) bars. Bottom panel: Left axis displays percentage (bars) of participants
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Mackinder et al. BMC Gastroenterology 2014, 14:99 Page 6 of 8
http://www.biomedcentral.com/1471-230X/14/99routine practice, height and weight z-scores deficits were
observed in children with T1DM+CD compared with
T1DM controls [16,17].
Weight gain is a recognised feature in individuals with
T1DM on intensive insulin therapy [24]. T1DM is often
characterised by weight loss prior to diagnosis of diabetes
and weight gain following initiation of insulin therapy.This is a confounder in previous studies that did not
account for fluctuations in growth at the start of insulin
therapy [11,13,17]. In the current study, all children with
T1DM and T1DM + CD were specified to have been
diagnosed with T1DM diagnosis more than two years
prior to CD diagnosis to eliminate the remission phase
after T1DM diagnosis. Moreover as the T1DM control
Mackinder et al. BMC Gastroenterology 2014, 14:99 Page 7 of 8
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duration of T1DM at CD onset (baseline) any influence
would be reflected evenly in both groups.
Our results are consistent with many studies reporting
no significant difference in HbA1c levels between indi-
viduals with T1DM and T1DM+CD before or after the
diagnosis of CD [12,13]. However, other studies have
reported lower HbA1c levels [14,16] or raised HbA1c
levels [25], along with a reduction in insulin requirements
and an increase in the number of hypoglycaemic episodes
in the period prior to CD diagnosis [11,12]. This was
attributed by the authors to a possible destruction of
the intestinal mucosa impinging nutrient absorption
[14]. In the current study, HbA1c levels were raised sig-
nificantly one and two years post CDx in the T1DM +
CD children, however a similar increase was observed
in those with T1DM which suggests that this is a feature
of T1DM disease progression rather than a result of CD
diagnosis. This may be due to adolescents presenting
poorer adherence to insulin therapy [26] and a large
proportion of T1DM+CD are diagnosed during this age.
The absence of significant fluctuations in HbA1c levels
in the children with T1DM + CD in our study may be a
result of the regular screening practices, predisposing
to the earlier diagnosis of CD, but also due to the high
level of dietetic supervision that these children receive
in our centre.
Strict compliance to a GFD is associated with mucosal
histology restoration and improved nutritional status
in people with CD but adherence is difficult to assess
accurately and has been frequently over-looked in
studies [7,11,14,15]. In this study a significantly lower
proportion of T1DM+CD children presented with nor-
mal tTg levels (<7.0 U/ml) one year post CD diagnosis
than those with CD; by two years the majority of children
in both groups had tTg levels within the normal values.
This may reflect that people with T1DM+CD need more
time to adapt to the challenges and dietary management
of both conditions particularly as the large majority were
diagnosed during adolescence, when adherence to GFD
is reported between 25-60% [18,19]. On the other hand,
active on-going symptoms in those with CD may encour-
age adherence to a GFD making the dietary changes
more acceptable. Moreover, individuals with T1DM+CD
identified by serological testing with “silent” CD have an
absence of overt clinical symptoms, therefore the GFD
may be perceived as of secondary priority to the manage-
ment of diabetes and its associated complications.
One year prior to CD diagnosis, the mean change in
BMI z-scores in the children with T1DM tended to
increase but in those with T1DM + CD, the average
change in BMI z-scores were significantly lower and
negative. These differences in nutritional status change
may indicate the onset of CD before diagnosis, whichmight have affected nutrient absorption and subsequently
nutritional status. This pattern was reversed within two
years after the introduction of GFD, supporting our
speculations. Moreover it is possible that further deteri-
oration might have been prevented by routine screening
and early detection of CD in these people, limiting the
time CD would remain undiagnosed. In children with CD
it is well established that the longer active CD remains
undiagnosed and the older the age before this is diagnosed
are both associated with complications like gastroin-
testinal malignancy [17] and osteoporosis [27,28]. Yet
in T1DM the long-term effects of sub-clinical CD are
not well investigated and remain grossly unknown. It
has been speculated that undetected and untreated CD
may compound the effects of T1DM and increase the risk
of the developing of CD associated complications, delay-
ing the benefits to nutritional status and psychological
wellbeing associated with GFD introduction [1,29].
The retrospective design of this study is an inherent
limitation as often leads to incomplete datasets and
sample selection bias Moreover, data on insulin require-
ments and number of hypoglycaemic episodes, which
would reflect a better assessment of T1DM management,
were not available.
High quality longitudinal studies are required to under-
stand the long-term outcomes of T1DM+CD. Due to
lack of evidence the National Institute of Clinical Excel-
lence (NICE) in the UK revised its guidelines reducing
routine screening to a single screen at T1DM diagnosis
[30]. Evidence from this study suggests that regular
screening may have prevented the further decline in
nutritional status and tackled deterioration of growth
velocity in people with silent T1DM + CD.Conclusions
The early diagnosis of CD and initiation of a GFD under
regular dietetic supervision may prevent further deterior-
ation in the nutritional status of children with T1DM+CD
and may also reduce the prospect of CD complications
without having any evident impact on T1DM control. In
centres where routine screening for CD does not occur,
clinicians should remain vigilant for these clinical features
and test for it accordingly.Additional file
Additional file 1: Evidence table of recent studies exploring the
impact of dual diagnosis of Type 1 diabetes and coeliac disease on
anthropometry, growth and disease management.Abbreviations
CD: Coeliac disease; T1DM: Type 1 Diabetes Mellitus; T1DM + DM: Type 1
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